{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:15:03Z","timestamp":1778152503847,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and is generally associated with a favorable prognosis. However, a subset of these tumors exhibits more aggressive behavior, underscoring the need for refined molecular and immunohistochemical characterization to improve diagnostic precision and prognostic stratification. Given the shared embryologic origin of the thyroid gland and gastrointestinal tract from the endoderm, intestinal differentiation markers (CDX2 and SATB2) and alterations in DNA mismatch repair (MMR) pathways, including MLH1 promoter methylation, may represent biologically relevant features in thyroid tumors. This study performed MLH1 promoter methylation analysis by pyrosequencing and protein expression of MLH1, PMS2, MSH2, MSH6, SATB2 and CDX2 by immunohistochemistry in 63 PTCs. Clinicopathological and molecular data were also collected for comparative analyses and correlation with progression-free survival (PFS). All PTCs retained expression of MMR proteins (MLH1, PMS2, MSH2, and MSH6), including the three tumors with MLH1 promoter hypermethylation. CDX2 positivity was detected in only two (3.2%) PTCs (classic and follicular subtypes), and SATB2 expression was absent in all cases. No significant association was identified between MLH1 promoter methylation, MMR protein expression, CDX2 or SATB2 expression, and PFS. In contrast, venous invasion was confirmed as a significant predictor of worse PFS (HR\u2009=\u20093.34; 95% CI 1.27\u20138.76;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014) in univariate analysis. MLH1 promoter methylation, MMR deficiency, and CDX2 are rare events in PTC and do not appear to influence PFS. Although infrequent, the expression of CDX2 is not exclusive to any PTC subtype.\n                  <\/jats:p>","DOI":"10.1007\/s00428-026-04557-4","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:51:46Z","timestamp":1778151106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MLH1 promoter methylation, mismatch repair and intestinal differentiation markers in papillary thyroid carcinoma: real-world evidence from Galicia (Northwest Spain)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-086X","authenticated-orcid":false,"given":"F\u00e1bio Fran\u00e7a Vieira e","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4232","authenticated-orcid":false,"given":"Guillermo","family":"Prada-Ramallal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-4200","authenticated-orcid":false,"given":"Marina","family":"Di Domenico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-7768","authenticated-orcid":false,"given":"Mar\u00eda Elena","family":"Pad\u00edn-Iruegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0423-4696","authenticated-orcid":false,"given":"Laura Isabel","family":"Rojo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-3079","authenticated-orcid":false,"given":"Susana Bel\u00e9n","family":"Bravo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2314-4548","authenticated-orcid":false,"given":"Paola","family":"Della Monica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5630-3956","authenticated-orcid":false,"given":"Federica","family":"Colapietra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-1415","authenticated-orcid":false,"given":"Andrea","family":"Ballini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-8914","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Cameselle-Teijeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"21","key":"4557_CR1","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1097\/CM9.0000000000003284","volume":"137","author":"Z Lyu","year":"2024","unstructured":"Lyu Z, Zhang Y, Sheng C, Huang Y, Zhang Q, Chen K (2024) Global burden of thyroid cancer in 2022: incidence and mortality estimates from GLOBOCAN. Chin Med J (Engl) 137(21):2567\u20132576. https:\/\/doi.org\/10.1097\/CM9.0000000000003284","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"4557_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/0959-8049(93)90292-n","volume":"29A","author":"W Langsteger","year":"1993","unstructured":"Langsteger W, K\u00f6ltringer P, Wolf G, Dominik K, Buchinger W, Binter G, Lax S, Eber O (1993) The impact of geographical, clinical, dietary and radiation-induced features in epidemiology of thyroid cancer. Eur J Cancer 29A(11):1547\u201353. https:\/\/doi.org\/10.1016\/0959-8049(93)90292-n","journal-title":"Eur J Cancer"},{"issue":"7","key":"4557_CR3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","volume":"31","author":"CM Kitahara","year":"2022","unstructured":"Kitahara CM, Schneider AB (2022) Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev 31(7):1284\u20131297. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-1440","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4557_CR4","unstructured":"WHO Classification of Tumours Editorial Board (2025) Endocrine and neuroendocrine tumours [Internet]. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/53"},{"issue":"8","key":"4557_CR5","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41379-018-0070-2","volume":"31","author":"JM Cameselle-Teijeiro","year":"2018","unstructured":"Cameselle-Teijeiro JM, Peteiro-Gonz\u00e1lez D, Caneiro-G\u00f3mez J, S\u00e1nchez-Ares M, Abdulkader I, Eloy C, Melo M, Amendoeira I, Soares P, Sobrinho-Sim\u00f5es M (2018) Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT\/\u00df-catenin pathway. Mod Pathol 31(8):1168\u20131179. https:\/\/doi.org\/10.1038\/s41379-018-0070-2","journal-title":"Mod Pathol"},{"issue":"3","key":"4557_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12022-021-09683-0","volume":"32","author":"B Boyraz","year":"2021","unstructured":"Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nos\u00e9 V, Mete O (2021) Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol 32(3):327\u2013335. https:\/\/doi.org\/10.1007\/s12022-021-09683-0","journal-title":"Endocr Pathol"},{"issue":"3","key":"4557_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/or.2024.8778","volume":"52","author":"S Cameselle-Garc\u00eda","year":"2024","unstructured":"Cameselle-Garc\u00eda S, Abdulkader-Nallib I, S\u00e1nchez-Ares M, Cameselle-Teijeiro JM (2024) Cribriform morular thyroid carcinoma: clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review). Oncol Rep 52(3):119. https:\/\/doi.org\/10.3892\/or.2024.8778","journal-title":"Oncol Rep"},{"issue":"11","key":"4557_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41574-020-00414-9","volume":"16","author":"CM Kitahara","year":"2020","unstructured":"Kitahara CM, Sosa JA (2020) Understanding the ever-changing incidence of thyroid cancer. Nat Rev Endocrinol 16(11):617\u2013618. https:\/\/doi.org\/10.1038\/s41574-020-00414-9","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"4557_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA, Abdel-Rahman O, Bahig H, Ho C, Hasan OK, Lemieux B, Winquist E, Wong R, Wu J, Chau N, Ezzat S (2024) Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol 35(4):293\u2013308. https:\/\/doi.org\/10.1007\/s12022-024-09836-x","journal-title":"Endocr Pathol"},{"issue":"2","key":"4557_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.patol.2026.100859","volume":"59","author":"I Ruz-Caracuel","year":"2026","unstructured":"Ruz-Caracuel I, Alonso-Gordoa T, Hern\u00e1ndez S, Hernando J, Rodrigo-Calvo MT, Jimenez-Fonseca P, Quiceno-Arias HD, Lorenzo-Lorenzo I, Bella-Cueto MR, Iglesias C, Cameselle-Teijeiro JM, Capdevila J (2026) SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer. Rev Esp Patol 59(2):100859. https:\/\/doi.org\/10.1016\/j.patol.2026.100859","journal-title":"Rev Esp Patol"},{"issue":"1","key":"4557_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12022-021-09666-1","volume":"32","author":"P Soares","year":"2021","unstructured":"Soares P, P\u00f3voa AA, Melo M, Vinagre J, M\u00e1ximo V, Eloy C, Cameselle-Teijeiro JM, Sobrinho-Sim\u00f5es M (2021) Molecular pathology of non-familial follicular epithelial-derived thyroid cancer in adults: from RAS\/BRAF-like tumor designations to molecular risk stratification. Endocr Pathol 32(1):44\u201362. https:\/\/doi.org\/10.1007\/s12022-021-09666-1","journal-title":"Endocr Pathol"},{"issue":"12","key":"4557_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1242\/dev.145615","volume":"144","author":"M Nilsson","year":"2017","unstructured":"Nilsson M, Fagman H (2017) Development of the thyroid gland. Development 144(12):2123\u20132140. https:\/\/doi.org\/10.1242\/dev.145615","journal-title":"Development"},{"issue":"1","key":"4557_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04177-7","volume":"26","author":"MR Keivany","year":"2026","unstructured":"Keivany MR, Shojae Asrami E, Besharatloo M, Latifi H, Barjasteh AH (2026) Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors. Cancer Cell Int 26(1):151. https:\/\/doi.org\/10.1186\/s12935-026-04177-7","journal-title":"Cancer Cell Int"},{"key":"4557_CR14","doi-asserted-by":"publisher","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. (2020) Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105","DOI":"10.1200\/JCO.19.02105"},{"issue":"2","key":"4557_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/10507256251409138","volume":"36","author":"S Hamidi","year":"2026","unstructured":"Hamidi S, Vodopivec DM, Busaidy NL, Gule-Monroe M, Akhave NS, Banuchi VE, Ferraroto R, Fournier I, Gunn GB, Iyer PC, Lee A, Maniakas A, Marczyk VR, Ning MS, Sousa LG, Spiotto MT, Waguespack SG, Wang JR, Zafereo ME, Cabanillas ME, Dadu R (2026) Real-world experience with Lenvatinib plus Pembrolizumab in metastatic BRAF wild-type anaplastic thyroid carcinoma. Thyroid 36(2):153\u2013161. https:\/\/doi.org\/10.1177\/10507256251409138","journal-title":"Thyroid"},{"issue":"3","key":"4557_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24455","volume":"10","author":"N Ma","year":"2024","unstructured":"Ma N, Zhou T, Li C, Luo X, Chen S, Zhu XY, Chen XH, Liu H, Tian HY, Gao QJ, Zhao DW (2024) A pan-cancer analysis of the prognosis and immune infiltration of eEF1A2 and its potential function in thyroid carcinoma. Heliyon 10(3):e24455. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24455","journal-title":"Heliyon"},{"key":"4557_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-97508-5","volume-title":"Quick reference handbook for surgical pathologists","author":"N Rehtman","year":"2019","unstructured":"Rehtman N, Baine MK, Bishop JA (2019) Quick reference handbook for surgical pathologists, 2nd ed. Springer, Cham, Switzerland","edition":"2nd ed"},{"issue":"19","key":"4557_CR18","doi-asserted-by":"publisher","first-page":"11064","DOI":"10.1111\/jcmm.15755","volume":"24","author":"SK Roy","year":"2020","unstructured":"Roy SK, Shrivastava A, Srivastav S, Shankar S, Srivastava RK (2020) SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med 24(19):11064\u201311069. https:\/\/doi.org\/10.1111\/jcmm.15755","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4557_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Sim\u00f5es M, Tallini G, Mete O (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33(1):27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr Pathol"},{"issue":"1","key":"4557_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-024-01645-2","volume":"18","author":"KE Higgins","year":"2024","unstructured":"Higgins KE, Sadow PM, Johnson DN, Wang P, Wanjari P, Cipriani NA (2024) Columnar cell thyroid carcinoma: a heterogeneous entity demonstrating overlap between papillary thyroid carcinoma and follicular neoplasms. Head Neck Pathol 18(1):39. https:\/\/doi.org\/10.1007\/s12105-024-01645-2","journal-title":"Head Neck Pathol"},{"issue":"2","key":"4557_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67(2):93\u201399. https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4557_CR22","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, M\u00e1ximo V, Sobrinho-Sim\u00f5es M, Soares P (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754-65. https:\/\/doi.org\/10.1210\/jc.2013-3734","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4557_CR23","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3892\/ol.2019.10131","volume":"17","author":"J Zhao","year":"2019","unstructured":"Zhao J, Liu P, Yu Y, Zhi J, Zheng X, Yu J, Gao M (2019) Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer. Oncol Lett 17(5):4661\u20134666. https:\/\/doi.org\/10.3892\/ol.2019.10131","journal-title":"Oncol Lett"},{"issue":"12","key":"4557_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/abbs\/gmy128","volume":"50","author":"W Zhang","year":"2018","unstructured":"Zhang W, Li K, Zhong X, Yan H, Tong G (2018) CDX2 is essential for human IVF early embryonic development. Acta Biochim Biophys Sin (Shanghai) 50(12):1274\u20131279. https:\/\/doi.org\/10.1093\/abbs\/gmy128","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"6","key":"4557_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1309\/AJCP1BGCA6MFCNKH","volume":"138","author":"J Cameselle-Teijeiro","year":"2012","unstructured":"Cameselle-Teijeiro J, Alberte-Lista L, Peteiro-Gonz\u00e1lez D, Abdulkader-Nallib I, Reyes-Sant\u00edas R, Soares P, Sobrinho-Sim\u00f5es M (2012) CDX2 expression in some variants of papillary thyroid carcinoma. Am J Clin Pathol 138(6):907\u2013909. https:\/\/doi.org\/10.1309\/AJCP1BGCA6MFCNKH","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"4557_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1309\/AJCPXE3PUBWVZCGZ","volume":"137","author":"ML Enriquez","year":"2012","unstructured":"Enriquez ML, Baloch ZW, Montone KT, Zhang PJ, LiVolsi VA (2012) CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol 137(5):722\u2013726. https:\/\/doi.org\/10.1309\/AJCPXE3PUBWVZCGZ","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"4557_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1089\/thy.2012.0455","volume":"23","author":"V Sujoy","year":"2013","unstructured":"Sujoy V, Pinto A, Nos\u00e9 V (2013) Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid 23(6):714\u20139. https:\/\/doi.org\/10.1089\/thy.2012.0455","journal-title":"Thyroid"},{"issue":"6","key":"4557_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/cyt.13288","volume":"34","author":"T Kumar","year":"2023","unstructured":"Kumar T, Khanna N, Tewari P, Bharti S, Bhadani PP (2023) FNA cytology of columnar cell variant of papillary thyroid carcinoma: a case report with review of literature. Cytopathology 34(6):617\u2013621. https:\/\/doi.org\/10.1111\/cyt.13288","journal-title":"Cytopathology"},{"issue":"4","key":"4557_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5858\/arpa.2021-0317-OA","volume":"147","author":"D Dum","year":"2023","unstructured":"Dum D, Kromm D, Lennartz M, De Wispelaere N, B\u00fcscheck F, Luebke AM, Burandt E, Menz A, Kluth M, Hube-Magg C, Hinsch A, H\u00f6flmayer D, Weidemann S, Fraune C, M\u00f6ller K, Lebok P, Sauter G, Simon R, Uhlig R, Wilczak W, Minner S, Krech R, Bernreuther C, Marx A, Steurer S, Jacobsen F, Clauditz T, Krech T (2023) SATB2 expression in human tumors: a tissue microarray study on more than 15 000 tumors. Arch Pathol Lab Med 147(4):451\u2013464. https:\/\/doi.org\/10.5858\/arpa.2021-0317-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"4557_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaf124","volume":"165","author":"B Maguire","year":"2026","unstructured":"Maguire B, Prehn JHM, Burke JP (2026) Loss of SATB2 in colorectal cancer is associated with inferior survival and adverse clinicopathologic features: a meta-analysis. Am J Clin Pathol 165(1):aqaf124. https:\/\/doi.org\/10.1093\/ajcp\/aqaf124","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"4557_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/mc.23631","volume":"63","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang J, Huang D, Liu Z, Lu T, Cui C, Li Z (2024) Single-cell sequencing reveals SATB2\/NOTCH1 signaling promotes the progression of malignancy of epithelial cells from papillary thyroid cancer. Mol Carcinog 63(1):22\u201333. https:\/\/doi.org\/10.1002\/mc.23631","journal-title":"Mol Carcinog"},{"issue":"4","key":"4557_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12022-024-09833-0","volume":"35","author":"D Nkosi","year":"2024","unstructured":"Nkosi D, Crowe WE, Altman BJ, Oltvai ZN, Giampoli EJ, Velez MJ (2024) SATB2 is an emergent biomarker of anaplastic thyroid carcinoma: a series with comprehensive biomarker and molecular studies. Endocr Pathol 35(4):432\u2013441. https:\/\/doi.org\/10.1007\/s12022-024-09833-0","journal-title":"Endocr Pathol"},{"issue":"2","key":"4557_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00418-023-02202-8","volume":"160","author":"F Grillo","year":"2023","unstructured":"Grillo F, Paudice M, Gambella A, Bozzano S, Sciallero S, Puccini A, Lastraioli S, Dono M, Parente P, Vanoli A, Angerilli V, Fassan M, Mastracci L (2023) Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens. Histochem Cell Biol 160(2):113\u2013125. https:\/\/doi.org\/10.1007\/s00418-023-02202-8","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"4557_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12022-025-09883-y","volume":"36","author":"V Zambelli","year":"2025","unstructured":"Zambelli V, Orlando G, Fornaro M, Vocino Trucco G, Rapa I, Napoli F, Cappia S, Daniele L, Piana S, Papotti M, Volante M (2025) High prevalence of potential molecular therapeutic targets in poorly differentiated thyroid carcinoma. Endocr Pathol 36(1):38. https:\/\/doi.org\/10.1007\/s12022-025-09883-y","journal-title":"Endocr Pathol"},{"issue":"2","key":"4557_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jmoldx.2023.10.005","volume":"26","author":"NC Helderman","year":"2024","unstructured":"Helderman NC, Andini KD, van Leerdam ME, van Hest LP, Hoekman DR, Ahadova A, Bajwa-Ten Broeke SW, Bosse T, van der Logt EMJ, Imhann F, Kloor M, Langers AMJ, Smit VTHBM, Terlouw D, van Wezel T, Morreau H, Nielsen M (2024) MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome. J Mol Diagn 26(2):106\u2013114. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.10.005","journal-title":"J Mol Diagn"},{"issue":"2","key":"4557_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cncr.23548","volume":"113","author":"H Guan","year":"2008","unstructured":"Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, Teng W, Xing M (2008) Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 113(2):247\u2013255. https:\/\/doi.org\/10.1002\/cncr.23548","journal-title":"Cancer"},{"key":"4557_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2407-13-79","volume":"13","author":"JC Santos","year":"2013","unstructured":"Santos JC, Bastos AU, Cerutti JM, Ribeiro ML (2013) Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma. BMC Cancer 13:79. https:\/\/doi.org\/10.1186\/1471-2407-13-79","journal-title":"BMC Cancer"},{"issue":"1","key":"4557_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/CBM-182265","volume":"25","author":"A Botezatu","year":"2019","unstructured":"Botezatu A, Iancu IV, Plesa A, Manda D, Popa O, Bostan M, Mihaila M, Albulescu A, Fudulu A, Vladoiu SV, Huica I, Dobrescu R, Anton G, Badiu C (2019) Methylation of tumour suppressor genes associated with thyroid cancer. Cancer Biomark 25(1):53\u201365. https:\/\/doi.org\/10.3233\/CBM-182265","journal-title":"Cancer Biomark"},{"issue":"1","key":"4557_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89403-0","volume":"11","author":"B Evren","year":"2021","unstructured":"Evren B, Y\u0131lmaz S, Karada\u011f N, Sertkaya A\u00c7, Topalo\u011flu \u00d6, K\u0131l\u0131n\u00e7 F (2021) DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter. Sci Rep 11(1):9932. https:\/\/doi.org\/10.1038\/s41598-021-89403-0","journal-title":"Sci Rep"},{"issue":"12","key":"4557_CR40","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41379-022-01149-w","volume":"35","author":"KTS Aiyer","year":"2022","unstructured":"Aiyer KTS, Doeleman T, Ryan NA, Nielsen M, Crosbie EJ, Smit VTHBM, Morreau H, Goeman JJ, Bosse T (2022) Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis. Mod Pathol 35(12):1775\u20131783. https:\/\/doi.org\/10.1038\/s41379-022-01149-w","journal-title":"Mod Pathol"},{"issue":"25","key":"4557_CR41","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718\u20132726. https:\/\/doi.org\/10.1200\/JCO.2014.55.5094","journal-title":"J Clin Oncol"},{"issue":"1","key":"4557_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.k08e-208","volume":"56","author":"Y Ito","year":"2009","unstructured":"Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89\u201397. https:\/\/doi.org\/10.1507\/endocrj.k08e-208","journal-title":"Endocr J"},{"issue":"12","key":"4557_CR43","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1530\/EC-21-0410","volume":"10","author":"M Al-Masri","year":"2021","unstructured":"Al-Masri M, Al-Shobaki T, Al-Najjar H, Iskanderian R, Younis E, Abdallah N, Tbakhi A, Haddad H, Al-Masri M, Obeid Z, Jarrar A (2021) BRAF V600E mutation in papillary thyroid carcinoma: it\u2019s relation to clinical features and oncologic outcomes in a single cancer centre experience. Endocr Connect 10(12):1531\u20131537. https:\/\/doi.org\/10.1530\/EC-21-0410","journal-title":"Endocr Connect"},{"issue":"3","key":"4557_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc3025","volume":"11","author":"P Mart\u00ednez","year":"2011","unstructured":"Mart\u00ednez P, Blasco MA (2011) Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 11(3):161\u2013176. https:\/\/doi.org\/10.1038\/nrc3025","journal-title":"Nat Rev Cancer"},{"key":"4557_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.643151","volume":"12","author":"VR da Costa","year":"2021","unstructured":"da Costa VR, Bim LV, Pacheco E Silva LDP, Colloza-Gama GA, Bastos AU, Delcelo R, Oler G, Cerutti JM (2021) Advances in detecting low prevalence somatic TERT promoter mutations in papillary thyroid carcinoma. Front Endocrinol (Lausanne) 12:643151. https:\/\/doi.org\/10.3389\/fendo.2021.643151","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"4557_CR46","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1210\/jc.2016-2785","volume":"102","author":"M Melo","year":"2017","unstructured":"Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Sim\u00f5es M, Soares P (2017) TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J Clin Endocrinol Metab 102(6):1898\u20131907. https:\/\/doi.org\/10.1210\/jc.2016-2785","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"4557_CR47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1089\/thy.2018.0695","volume":"29","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N (2019) TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid 29(8):1105\u20131114. https:\/\/doi.org\/10.1089\/thy.2018.0695","journal-title":"Thyroid"},{"issue":"4","key":"4557_CR48","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cancers13040648","volume":"13","author":"J Park","year":"2021","unstructured":"Park J, Lee S, Kim K, Park H, Ki CS, Oh YL, Shin JH, Kim JS, Kim SW, Chung JH, Kim TH (2021) TERT promoter mutations and the 8th edition TNM classification in predicting the survival of thyroid cancer patients. Cancers (Basel) 13(4):648. https:\/\/doi.org\/10.3390\/cancers13040648","journal-title":"Cancers (Basel)"},{"key":"4557_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1728045","volume":"16","author":"Q Yu","year":"2026","unstructured":"Yu Q, Liu H (2026) Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma. Front Endocrinol (Lausanne) 16:1728045. https:\/\/doi.org\/10.3389\/fendo.2025.1728045","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4557_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","volume":"32","author":"M Volante","year":"2021","unstructured":"Volante M, Lam AK, Papotti M, Tallini G (2021) Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 32(1):63\u201376. https:\/\/doi.org\/10.1007\/s12022-021-09665-2","journal-title":"Endocr Pathol"},{"issue":"11","key":"4557_CR51","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11(11):761\u2013774. https:\/\/doi.org\/10.1038\/nrc3106","journal-title":"Nat Rev Cancer"},{"key":"4557_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1414492","volume":"14","author":"M Fei","year":"2024","unstructured":"Fei M, Ding D, Ouyang X, Shen W, Zhang F, Zhang B, Qin L (2024) The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules. Front Oncol 14:1414492. https:\/\/doi.org\/10.3389\/fonc.2024.1414492","journal-title":"Front Oncol"},{"issue":"1","key":"4557_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12022-026-09910-6","volume":"37","author":"LQ Wong","year":"2026","unstructured":"Wong LQ, Baloch ZW (2026) Impact of co-mutations and genetic variations on malignancy risk in RAS-positive indeterminate thyroid nodules: an institutional experience. Endocr Pathol 37(1):13. https:\/\/doi.org\/10.1007\/s12022-026-09910-6","journal-title":"Endocr Pathol"},{"issue":"11","key":"4557_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113186","volume":"12","author":"AA P\u00f3voa","year":"2020","unstructured":"P\u00f3voa AA, Teixeira E, Bella-Cueto MR, Melo M, Oliveira MJ, Sobrinho-Sim\u00f5es M, Maciel J, Soares P (2020) Clinicopathological features as prognostic predictors of poor outcome in papillary thyroid carcinoma. Cancers (Basel) 12(11):3186. https:\/\/doi.org\/10.3390\/cancers12113186","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4557_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.17849\/insm-47-03-143-158.1","volume":"47","author":"AF Milano","year":"2018","unstructured":"Milano AF (2018) Thyroid cancer: 20-year comparative mortality and survival analysis of six thyroid cancer histologic subtypes by age, sex, race, stage, cohort entry time-period and disease duration (SEER*Stat 8.3.2) a systematic review of 145,457 Cases for Diagnosis Years 1993\u20132013. J Insur Med 47(3):143\u2013158. https:\/\/doi.org\/10.17849\/insm-47-03-143-158.1","journal-title":"J Insur Med"},{"issue":"1","key":"4557_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Gosnell JE, Roman SA (2020) Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 16(1):17\u201329. https:\/\/doi.org\/10.1038\/s41574-019-0263-x","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"4557_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112119","volume":"16","author":"FFVE Silva","year":"2024","unstructured":"Silva FFVE, Ballini A, Caponio VCA, P\u00e9rez-Say\u00e1ns M, Cort\u00e9s MG, Rojo-\u00c1lvarez LI, Garc\u00eda-Garc\u00eda A, Suar\u00e9z-Pe\u00f1aranda JM, Di Domenico M, Pad\u00edn-Iruegas ME (2024) Insights into MLH1 methylation in endometrial adenocarcinoma through pyrosequencing analysis: a retrospective observational study. Cancers (Basel) 16(11):2119. https:\/\/doi.org\/10.3390\/cancers16112119","journal-title":"Cancers (Basel)"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04557-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04557-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04557-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:51:51Z","timestamp":1778151111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04557-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":57,"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04557-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the Declaration of Helsinki (and later updates) and received approval from the Santiago-Lugo Research Ethics Committee (code: 2023\/532). Written informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors have no relevant financial interest in the products or companies described in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}